Our data as summarized here provide a novel mechanism that links nutrient surplus to SIRT1 repression and present PIAS4 as a potential druggable target for NASH intervention (Figure 6). This evidence concerns the gene PIAS4 and metabolic dysfunction-associated steatohepatitis.